Lynparza (olaparib) — Medica
Uterine leiomyosarcoma
Initial criteria
- age ≥ 18 years
- BRCA2-altered disease
- has tried at least one systemic regimen (e.g., dacarbazine, docetaxel, doxorubicin, epirubicin, gemcitabine, ifosfamide, trabectedin)
Approval duration
1 year